Pay in 4 interest-free payments of $7.10 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Most are gut-related, like nausea, heartburn, and diarrhea or constipation
RiskBenefit Perspective Despite theoretical concerns, the clinical reality is clear: GLP-1 therapies produce substantial weight loss Improve glycemic control and cardiometabolic outcomes Reduce cardiovascular risk in multiple studies When evaluating carcinogenicity risk, current evidence suggests: Strong rodent signals exist but may not translate to humans Long-term human data has not confirmed increased thyroid cancer risk Regulatory warnings remain precautionary rather than confirmatory Conclusion The GLP-1 receptor agonist classfrom Liraglutide to next-generation oral agents like Orforglipronrepresents one of the most transformative areas in metabolic medicine
Key Takeaways GLP-1s are not known to commonly cause direct changes in periods
GLP-3 is not the correct scientific term
Both companies could be great picks to ride the GLP-1 tailwind over the medium term, but as competition grows in this niche, they may see declining market share and pricing power
References Neeland IJ, et al
US$ 28.50
US$ 24.08
US$ 23.98
US$ 21.42
US$ 28.43
US$ 28.97
US$ 28.89
US$ 21.61
US$ 25.95
US$ 20.48
US$ 21.41
US$ 21.23
US$ 22.91
